28.07.2021 Vitruvia Medical AG  CH0461931419

DGAP-News: Vitruvia Medical AG: Successful certification for the reprocessing of 'critical C' devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices


 

DGAP-News: Vitruvia Medical AG / Key word(s): Regulatory Approval/Product Launch
Vitruvia Medical AG: Successful certification for the reprocessing of 'critical C' devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices

28.07.2021 / 10:00
The issuer is solely responsible for the content of this announcement.


Successful certification for the reprocessing of "critical C" devices - Vitruvia Medical now also providing circular systems for highest risk-level medical devices

Schönebeck, July 28, 2021 Vitruvia Medical, which specializes in circular systems for highly complex medical products, particularly robot-assisted surgery, now also holds
DIN EN ISO 13485:2016 (KRINKO) certification.

This means that Vitruvia Medical is now certified to reprocess all surgical instruments, including those classed at the highest "critical C" risk level. These include flexible endoscopes as well as all instruments and optics for robot-assisted surgery which are authorized for reprocessing by the manufacturer.

Reprocessing has to meet exceptionally high standards to ensure the highest level of patient safety, as well as the hygienic and functional safety of the reprocessed medical device. For this reason, the German Medical Devices Operator Ordinance (MPBetreibV) requires that facilities reprocessing "critical C" risk-level medical devices must have a quality management system that is certified in line with DIN EN ISO 13485 and takes the Robert Koch Institute's "KRINKO Recommendation" into account.

"This certification allows us to offer an efficient and quality-assured reprocessing service to hospitals for all surgical instruments both for robotics and endoscopy," says Vitruvia's Managing Director Rainer Grabow, explaining this innovative company's new milestone. These two service modules will be offered to hospitals under the names of RobotIQ and EndoscopyIQ.

The Vitruvia Medical Group has opened a 2,000 sqm Circular Clinic Supply Center for robotic instruments in Schönebeck, near Magdeburg - the first in Europe. After two years of renovation and upgrades, hospital instruments are now being prepared for reuse here under cleanroom conditions. With this sustainable concept, hospitals save both investment and operating costs when using robot-assisted surgical systems and also avoid the potential underuse of their own circular systems.

Further information: www.vitruvia-med.com

Press contact:
Wolfgang Böhm
BÖHM CONSULT AG
T +49 30 44 33 61 - 33
[email protected]



28.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vitruvia Medical AG
Kesselackerstr. 18
5611 Anglikon
Germany
Phone: +41 44 915 33 78
E-mail: [email protected]
Internet: www.vitruvia-med.com
ISIN: CH0461931419
Listed: Regulated Unofficial Market in Munich
EQS News ID: 1221995

 
End of News DGAP News Service

1221995  28.07.2021 

fncls.ssp?fn=show_t_gif&application_id=1221995&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 0,00 0,00 0,00 5,60 1,97 1,42 0,00
EBITDA1,2 0,00 0,00 0,00 -0,96 -0,75 -0,91 0,00
EBITDA-Marge3 0,00 0,00 0,00 -17,14 -38,07 -64,08
EBIT1,4 0,00 0,00 0,00 -1,31 -7,69 -1,24 0,00
EBIT-Marge5 0,00 0,00 0,00 -23,39 -390,36 -87,32 0,00
Jahresüberschuss1 0,00 0,00 0,00 -1,54 -7,71 -1,48 0,00
Netto-Marge6 0,00 0,00 0,00 -27,50 -391,37 -104,23 0,00
Cashflow1,7 0,00 0,00 0,00 -0,21 -0,78 -0,67 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 -0,85 -4,19 -0,59 -0,15
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vitruvia Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2PDWF 0,920 2,31
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,37
KBV KCV KUV EV/EBITDA
-1,18 - 1,63 -2,51
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 26.07.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2023 26.06.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
32,37% 3,84% -23,33% -60,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vitruvia Medical AG  ISIN: CH0461931419 können Sie bei EQS abrufen


Medtech , A2PDWF , 991 , MUN:991